Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...
Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., ...
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company with a market capitalization of $201.58 million, has announced the addition of two seasoned executives ...
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company with a market capitalization of $201.58 million, has announced the addition of two seasoned executives to ...
After hours: 7:41:16 p.m. EST ...
Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's ...
The NIH has lost two distinguished leaders as mass layoffs directed by the Trump administration hit federal health agencies.